Logo image of AIM

AIM IMMUNOTECH INC (AIM) Stock Fundamental Analysis

USA - NYSE Arca - NYSEARCA:AIM - US00901B3033 - Common Stock

1.37 USD
+0.07 (+5.38%)
Last: 11/21/2025, 8:11:33 PM
1.36 USD
-0.01 (-0.73%)
After Hours: 11/21/2025, 8:11:33 PM
Fundamental Rating

1

Taking everything into account, AIM scores 1 out of 10 in our fundamental rating. AIM was compared to 533 industry peers in the Biotechnology industry. AIM may be in some trouble as it scores bad on both profitability and health. AIM is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

AIM had negative earnings in the past year.
In the past year AIM has reported a negative cash flow from operations.
In the past 5 years AIM always reported negative net income.
AIM had a negative operating cash flow in each of the past 5 years.
AIM Yearly Net Income VS EBIT VS OCF VS FCFAIM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

AIM has a Return On Assets of -391.52%. This is amonst the worse of the industry: AIM underperforms 94.95% of its industry peers.
Industry RankSector Rank
ROA -391.52%
ROE N/A
ROIC N/A
ROA(3y)-132.89%
ROA(5y)-90.82%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AIM Yearly ROA, ROE, ROICAIM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

With an excellent Gross Margin value of 71.07%, AIM belongs to the best of the industry, outperforming 81.87% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for AIM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 71.07%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AIM Yearly Profit, Operating, Gross MarginsAIM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

0

2. Health

2.1 Basic Checks

AIM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AIM has been increased compared to 1 year ago.
AIM has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, AIM has a worse debt to assets ratio.
AIM Yearly Shares OutstandingAIM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
AIM Yearly Total Debt VS Total AssetsAIM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

AIM has an Altman-Z score of -162.69. This is a bad value and indicates that AIM is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -162.69, AIM is not doing good in the industry: 96.82% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -162.69
ROIC/WACCN/A
WACC8.29%
AIM Yearly LT Debt VS Equity VS FCFAIM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 0.10 indicates that AIM may have some problems paying its short term obligations.
AIM's Current ratio of 0.10 is on the low side compared to the rest of the industry. AIM is outperformed by 97.01% of its industry peers.
AIM has a Quick Ratio of 0.10. This is a bad value and indicates that AIM is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.10, AIM is doing worse than 96.82% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.1
Quick Ratio 0.1
AIM Yearly Current Assets VS Current LiabilitesAIM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

4

3. Growth

3.1 Past

AIM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -87.85%.
Looking at the last year, AIM shows a very negative growth in Revenue. The Revenue has decreased by -15.84% in the last year.
Measured over the past years, AIM shows a small growth in Revenue. The Revenue has been growing by 3.96% on average per year.
EPS 1Y (TTM)-87.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.47%
Revenue 1Y (TTM)-15.84%
Revenue growth 3Y7.99%
Revenue growth 5Y3.96%
Sales Q2Q%-25.71%

3.2 Future

AIM is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.20% yearly.
The Revenue is expected to grow by 281.45% on average over the next years. This is a very strong growth
EPS Next Y66.48%
EPS Next 2Y35.41%
EPS Next 3Y24.31%
EPS Next 5Y15.2%
Revenue Next Year-51.38%
Revenue Next 2Y-16.95%
Revenue Next 3Y306.65%
Revenue Next 5Y281.45%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AIM Yearly Revenue VS EstimatesAIM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
AIM Yearly EPS VS EstimatesAIM Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20 -30 -40

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

AIM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AIM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AIM Price Earnings VS Forward Price EarningsAIM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AIM Per share dataAIM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

A more expensive valuation may be justified as AIM's earnings are expected to grow with 24.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.41%
EPS Next 3Y24.31%

More info and screens

0

5. Dividend

5.1 Amount

AIM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AIM IMMUNOTECH INC

NYSEARCA:AIM (11/21/2025, 8:11:33 PM)

After market: 1.36 -0.01 (-0.73%)

1.37

+0.07 (+5.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-17 2025-11-17/amc
Earnings (Next)03-30 2026-03-30/amc
Inst Owners0.45%
Inst Owner Change0%
Ins Owners3.27%
Ins Owner Change0.01%
Market Cap3.71M
Revenue(TTM)170.00K
Net Income(TTM)-16.17M
Analysts80
Price Target24.48 (1686.86%)
Short Float %1.11%
Short Ratio0.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)46.29%
Min EPS beat(2)38.12%
Max EPS beat(2)54.46%
EPS beat(4)4
Avg EPS beat(4)35.78%
Min EPS beat(4)13.9%
Max EPS beat(4)54.46%
EPS beat(8)5
Avg EPS beat(8)11.51%
EPS beat(12)8
Avg EPS beat(12)8.7%
EPS beat(16)8
Avg EPS beat(16)0.86%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-84%
PT rev (3m)-84%
EPS NQ rev (1m)0%
EPS NQ rev (3m)87.81%
EPS NY rev (1m)64%
EPS NY rev (3m)78.03%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-41.49%
Revenue NY rev (3m)-64.75%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 30.68
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-20.25
EYN/A
EPS(NY)-3.41
Fwd EYN/A
FCF(TTM)-4.15
FCFYN/A
OCF(TTM)-4.04
OCFYN/A
SpS0.04
BVpS-2.42
TBVpS-3.22
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -391.52%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 71.07%
FCFM N/A
ROA(3y)-132.89%
ROA(5y)-90.82%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.1
Quick Ratio 0.1
Altman-Z -162.69
F-Score3
WACC8.29%
ROIC/WACCN/A
Cap/Depr(3y)119.66%
Cap/Depr(5y)104.37%
Cap/Sales(3y)164.13%
Cap/Sales(5y)265.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-87.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.47%
EPS Next Y66.48%
EPS Next 2Y35.41%
EPS Next 3Y24.31%
EPS Next 5Y15.2%
Revenue 1Y (TTM)-15.84%
Revenue growth 3Y7.99%
Revenue growth 5Y3.96%
Sales Q2Q%-25.71%
Revenue Next Year-51.38%
Revenue Next 2Y-16.95%
Revenue Next 3Y306.65%
Revenue Next 5Y281.45%
EBIT growth 1Y47.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y34.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.07%
OCF growth 3YN/A
OCF growth 5YN/A

AIM IMMUNOTECH INC / AIM FAQ

What is the ChartMill fundamental rating of AIM IMMUNOTECH INC (AIM) stock?

ChartMill assigns a fundamental rating of 1 / 10 to AIM.


What is the valuation status of AIM IMMUNOTECH INC (AIM) stock?

ChartMill assigns a valuation rating of 1 / 10 to AIM IMMUNOTECH INC (AIM). This can be considered as Overvalued.


Can you provide the profitability details for AIM IMMUNOTECH INC?

AIM IMMUNOTECH INC (AIM) has a profitability rating of 1 / 10.


What is the earnings growth outlook for AIM IMMUNOTECH INC?

The Earnings per Share (EPS) of AIM IMMUNOTECH INC (AIM) is expected to grow by 66.48% in the next year.